Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) such as Sézary syndrome or mycosis fungoides corresponds to an abnormal infiltration of T lymphocytes in the skin. CTCL cells have a heterogeneous phenotype and express cell adhesion molecules such as cutaneous lymphocyte antigen (CLA) supporting skin homing. The use...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative dermatology 2022-12, Vol.142 (12), p.3243-3252.e10
Main Authors: Peru, Sara, Prochazkova-Carlotti, Martina, Cherrier, Floriane, Velazquez, Joanne, Richard, Elodie, Idrissi, Yamina, Cappellen, David, Azzi-Martin, Lamia, Pham-Ledard, Anne, Beylot-Barry, Marie, Merlio, Jean-Philippe, Poglio, Sandrine
Format: Article
Language:English
Subjects:
Humans
Lymphoma, T-Cell, Cutaneous - pathology
Mycosis Fungoides - pathology
Sezary Syndrome - drug therapy
Sezary Syndrome - pathology
Skin Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous T-cell lymphoma (CTCL) such as Sézary syndrome or mycosis fungoides corresponds to an abnormal infiltration of T lymphocytes in the skin. CTCL cells have a heterogeneous phenotype and express cell adhesion molecules such as cutaneous lymphocyte antigen (CLA) supporting skin homing. The use of a mAb (HECA-452) against CLA significantly decreased transendothelial migration and survival of CTCL cells from patient samples and My-La cell line. The decrease of CLA expression by inhibition of its maturation enzyme, ST3 β-galactoside α-2,3-sialyltransferase 4, also impaired CTCL cell migration, proliferation, and survival. We confirmed in vivo that treatment with anti-CLA mAb decreased the tumorigenicity as well as dissemination of CTCL cells in different tissues compared with the control group. Our findings provide evidence of the involvement of CLA in CTCL cell migration and survival, supporting that CLA inhibition could represent an actionable therapy in patients with CTCL.
ISSN:0022-202X
1523-1747
DOI:10.1016/j.jid.2022.06.016